FDA asked its Peripheral and Central Nervous System
Drugs Advisory Committee to vote on nine questions related to the approvability
of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat patients
with relapsing-remitting multiple sclerosis (RRMS). Despite evidence of increased
rates of bradycardia at first dose, the development of macular edema and a
gradual decline in pulmonary function in clinical trials of the oral once-daily
sphingosine 1-phosphate (S1P) receptor